Definition Pathogenesis Clinical features presentation/ patient presentation Lab Reports/ diagnosis Lab and treatment Relation Treatment protocol Prognosis & Curability Disease Study Lab Co-Relation Syndrome Study Treatment Changing protocols Do's 4 Don'ts. Diagnosis and DD Drug Study/combination เคชเคฅเฅเคฏ เคต เค เคชเคฅเฅเคฏ study. On the above points explain Typhoid
Reading Document
Medical Text Search
typhoid fever definition pathogenesis Salmonella typhi
Medical Text Search
typhoid fever clinical features diagnosis lab reports Widal test blood culture
GradeResponse
GradeResponse
Medical Text Search
typhoid fever treatment antibiotics ciprofloxacin ceftriaxone azithromycin protocol
Medical Text Search
typhoid fever complications prognosis intestinal perforation hemorrhage
Now I'll synthesize a comprehensive, structured answer using retrieved sources plus my own clinical knowledge.
๐ฆ TYPHOID FEVER โ Complete Disease Study
1. DEFINITION
Typhoid fever (Enteric fever) is a systemic infectious disease caused by Salmonella enterica serotype Typhi (and less severely by Paratyphi A, B, C). It is a gram-negative, flagellated, non-spore-forming bacillus transmitted via the feco-oral route through contaminated food and water.
- Causative agent: Salmonella typhi (S. Typhi)
- Family: Enterobacteriaceae
- Reservoir: Humans only (no animal reservoir)
- Incubation period: 7โ21 days (average 10โ14 days)
- Infective dose: 10ยณโ10โถ organisms
2. PATHOGENESIS
(Harrison's Principles of Internal Medicine, 21st Ed., p. 4852)
The pathogenesis occurs in five sequential stages:
Stage 1 โ Ingestion & Intestinal Entry
- S. Typhi is ingested via contaminated food/water
- Survives gastric acid (aided by mucus buffering)
- Reaches the terminal ileum โ adheres to and penetrates M cells (microfold cells) overlying Peyer's patches
Stage 2 โ Macrophage Invasion (Key Step)
- After crossing the intestinal epithelium, S. Typhi is phagocytosed by macrophages
- Normally, macrophages destroy pathogens โ but S. Typhi evades killing via:
- PhoP/PhoQ regulatory system โ alters outer membrane (LPS, glycerophospholipids, outer membrane proteins) โ resists microbicidal activity
- Type III Secretion System (T3SS-2) โ injects bacterial proteins directly across the phagosome membrane into macrophage cytoplasm โ remodels the Salmonella-containing vacuole (SCV) โ promotes intracellular survival and replication
Stage 3 โ Bacteremia (Primary/Transient)
- Infected macrophages travel via mesenteric lymphatics โ thoracic duct โ bloodstream
- First bacteremia: clinically silent (incubation period)
- Bacteria seed: liver, spleen, bone marrow, gallbladder
Stage 4 โ Secondary Bacteremia
- After multiplication in reticuloendothelial system (RES)
- Massive release into bloodstream โ clinical illness begins
- Endotoxin (LPS) release โ fever, toxemia
Stage 5 โ Intestinal Phase (Week 2โ3)
- Re-invasion of intestinal wall via bile โ Peyer's patches
- Hyperplasia โ necrosis โ sloughing โ ulceration (along the long axis of bowel)
- Risk of perforation and hemorrhage
Ingestion โ M cells โ Macrophages (evade killing)
โ Mesenteric lymph nodes โ Bacteremia โ RES seeding
โ Secondary Bacteremia โ Intestinal ulceration
3. CLINICAL FEATURES / PATIENT PRESENTATION
Typhoid follows a stepwise weekly pattern:
๐๏ธ Week 1 โ Prodrome
| Feature | Details |
|---|---|
| Fever | Stepladder rise (39โ40ยฐC), peaks by end of week |
| Headache | Severe, frontal |
| Malaise & anorexia | Prominent |
| Dry cough | Present in ~30% |
| Constipation | More common than diarrhea initially (adults) |
| Relative bradycardia | Pulse-temperature dissociation (Faget's sign) |
๐๏ธ Week 2 โ Florid Illness
| Feature | Details |
|---|---|
| Rose spots | 2โ4 mm salmon-pink macules, trunk, blanch on pressure (10โ30% cases) |
| Sustained high fever | 40โ41ยฐC, plateau |
| Splenomegaly | Soft, tender spleen (80%) |
| Hepatomegaly | Mild (50%) |
| Abdominal distension | "Doughy" abdomen |
| Diarrhea | "Pea soup" diarrhea (especially children) |
| Toxemia | Delirium, stupor ("typhoid state") |
| Coated tongue | Central coat, red edges/tip ("Typhoid tongue") |
๐๏ธ Week 3 โ Complications or Resolution
- Intestinal perforation (1โ3%)
- Hemorrhage (10โ20%)
- Myocarditis, encephalopathy
- If untreated โ "typhoid state" (muttering delirium)
๐๏ธ Week 4 โ Recovery or Death
- Gradual defervescence if responding
- Relapse in 5โ10%
Key Signs Summary:
- Faget's sign (Relative bradycardia): Pulse rate lower than expected for fever
- Rose spots: Pathognomonic
- Doughy abdomen
- Groaning/toxic facies
4. LAB REPORTS / DIAGNOSIS
(Bailey & Love's Surgery, 28th Ed., p. 112)
๐ฌ Gold Standard: Blood Culture
| Test | Sensitivity | Best Time |
|---|---|---|
| Blood culture | 80โ90% (Week 1) | First week of fever |
| Bone marrow culture | 90โ95% | Any stage (even after antibiotics) |
| Stool culture | 30โ50% | Week 2โ3 |
| Urine culture | 25โ30% | Week 3 |
๐ฌ Widal Test
- Detects agglutinins against O antigen (somatic) and H antigen (flagellar) of S. Typhi & Paratyphi
- Significant titer: O โฅ 1:160, H โฅ 1:160 (in non-endemic areas)
- In endemic areas (India): single titer less reliable; four-fold rise in paired samples is diagnostic
- Limitations: False positives (malaria, liver disease, immunizations); false negatives (early disease, antibiotic pretreatment)
๐ฌ Rapid Serological Tests (especially when blood culture negative)
| Test | Detects | Notes |
|---|---|---|
| Typhidot | IgM + IgG anti-OMP | Sensitive & specific; results in 2โ3 hrs |
| Tubex | IgM anti-O9 | High specificity |
| MultiTest Dip-S-Tricks | IgG | Useful in limited settings |
๐ฌ CBC (Complete Blood Count)
| Parameter | Findings |
|---|---|
| WBC (leukocytes) | Leukopenia (3,000โ5,000/ฮผL) โ characteristic |
| Neutrophils | Decreased (relative lymphocytosis) |
| Eosinophils | Eosinopenia (disappearance of eosinophils โ significant finding) |
| Platelets | Thrombocytopenia (in severe disease) |
| ESR | Moderately elevated |
๐ฌ Other Labs
| Test | Finding |
|---|---|
| LFT | Mild elevation of ALT/AST (hepatitis typhosa) |
| Serum bilirubin | Slightly elevated |
| Urine | Albuminuria, cylindruria |
| CRP | Elevated |
| Procalcitonin | Elevated |
5. LAB AND TREATMENT RELATION
| Lab Finding | Clinical Significance | Treatment Implication |
|---|---|---|
| Blood culture + sensitivity | Identifies organism & antibiotic susceptibility | Directs targeted antibiotic therapy |
| Leukopenia | Confirms typhoid (rules out bacterial sepsis with leukocytosis) | Do NOT add unnecessary broad-spectrum antibiotics |
| Thrombocytopenia | Indicates severe disease | Monitor for hemorrhage; platelet transfusion if <20,000 |
| Elevated LFT | Hepatic involvement | Avoid hepatotoxic drugs (paracetamol high dose, anti-TB drugs) |
| Persistent eosinopenia | Ongoing active infection | Continue antibiotics; no early stoppage |
| Return of eosinophils | Sign of recovery (Typhoid convalescence sign) | May guide duration of antibiotic therapy |
| Widal rising titer | Active infection | Confirm with culture; initiate treatment |
| Positive culture on bone marrow | Definitive even after antibiotics | Proves ongoing infection; change/escalate antibiotics |
Pearl: Eosinopenia is an underused but powerful clinical-lab marker. Return of eosinophils signals recovery โ this is a classic teaching point in Indian clinical medicine.
6. TREATMENT PROTOCOL
๐ฅ First-Line Antibiotics (WHO/National Guidelines)
| Drug | Dose | Duration | Route |
|---|---|---|---|
| Azithromycin | 10โ20 mg/kg/day (max 1g/day) | 7 days | Oral |
| Ceftriaxone | 60โ75 mg/kg/day (max 2โ3 g/day) | 10โ14 days | IV/IM |
| Cefixime | 15โ20 mg/kg/day | 10โ14 days | Oral |
๐ฅ Second-Line (Sensitive strains only)
| Drug | Dose | Duration |
|---|---|---|
| Ciprofloxacin | 15 mg/kg BD | 10โ14 days |
| Ofloxacin | 10โ15 mg/kg/day | 10โ14 days |
| Chloramphenicol | 50โ75 mg/kg/day in 4 doses | 14 days |
| Ampicillin | 75โ100 mg/kg/day | 14 days |
| Co-trimoxazole | TMP 8 mg/kg + SMX 40 mg/kg/day | 14 days |
โ ๏ธ Fluoroquinolone resistance is widespread in South Asia โ Nalidixic acid resistance is used as a surrogate marker. Azithromycin and third-generation cephalosporins are now preferred.
๐ด MDR Typhoid (Multi-Drug Resistant โ resistant to Chloramphenicol, Ampicillin, Co-trimoxazole)
- Drug of choice: Ceftriaxone IV or Azithromycin oral
XDR Typhoid (Extensively Drug Resistant โ also resistant to Fluoroquinolones + 3rd gen cephalosporins)
- Reported from Pakistan (2018 outbreak)
- Drug of choice: Azithromycin or Carbapenems (Meropenem)
Supportive Treatment
- Antipyretics: Paracetamol (avoid NSAIDs/aspirin โ hemorrhage risk)
- IV fluids: for dehydration/toxemia
- Nutrition: soft, easily digestible diet (see Pathya)
- Dexamethasone (3 mg/kg loading, then 1 mg/kg q6h ร 48h): for severe typhoid with altered consciousness/shock (Harrison's protocol)
- Surgery: for intestinal perforation (peritonitis)
7. PROGNOSIS & CURABILITY
| Condition | Prognosis |
|---|---|
| Uncomplicated typhoid (treated) | Excellent โ recovery in 2โ4 weeks; mortality <1% |
| Untreated typhoid | Mortality 10โ30% |
| With intestinal perforation | Mortality 10โ32% even with surgery |
| XDR typhoid | Prolonged illness; depends on carbapenem availability |
| Relapse rate | 5โ10% (occurs 1โ3 weeks after apparent recovery) |
| Chronic carrier state | 1โ4% (especially with gallbladder disease) |
Curability: Typhoid is completely curable with appropriate antibiotics. Key determinants:
- Early diagnosis and treatment initiation
- Correct antibiotic based on sensitivity
- No complications
- Adequate nutrition and rest
Chronic carriers (especially biliary carriers) may require:
- Ciprofloxacin 750 mg BD ร 4 weeks, OR
- Cholecystectomy if gallstones are present
8. DISEASE STUDY โ Key Epidemiological & Microbiological Facts
| Feature | Detail |
|---|---|
| Organism | Salmonella enterica serovar Typhi |
| Gram stain | Gram-negative rod |
| Motility | Motile (peritrichous flagella) |
| Antigens | O (somatic, lipopolysaccharide), H (flagellar), Vi (capsular โ virulence antigen) |
| Vi antigen | Inhibits phagocytosis; important for virulence and vaccine development |
| Culture media | MacConkey agar (colorless/NLF colonies), Wilson-Blair bismuth sulphite agar (black colonies โ characteristic) |
| Incubation (lab) | 24โ48 hrs aerobic |
| Global burden | ~11โ21 million cases/year; ~128,000โ161,000 deaths/year |
| High-burden regions | South Asia, Southeast Asia, sub-Saharan Africa |
| Mode of transmission | Feco-oral: contaminated water > food > flies |
| Seasonal peak | Summer and monsoon (India) |
| Vaccine | Ty21a (oral, live attenuated); Vi polysaccharide (parenteral); Vi-conjugate (Typbar-TCV) |
9. LAB CORRELATION (Clinico-Pathological)
| Clinical Stage | Lab Correlation |
|---|---|
| Week 1 (bacteremia) | Blood culture positive; WBC โ; Widal may be negative |
| Week 2 (florid) | Widal O+H titers rising; LFT mildly abnormal; stool culture may become positive |
| Week 3 (complications) | Thrombocytopenia; rising CRP; if perforation โ leukocytosis (unusual), X-ray air under diaphragm |
| Recovery | Eosinophils return; WBC normalizes; cultures clear |
| Chronic carrier | Stool/bile cultures persistently positive; Vi antibody titer elevated (useful screening test) |
Vi Antibody Test: A rising Vi antibody titer helps identify chronic biliary carriers โ useful epidemiologically and in contact tracing.
10. SYNDROME STUDY
Typhoid can present with or cause several important syndromes and special manifestations:
๐ท Typhoid State (Muttering Delirium)
- Severe toxemia: patient lies with eyes open, mutters incoherently, picks at bedclothes
- Represents severe CNS involvement
- Treat with dexamethasone + antibiotics
๐ท Typhoid Hepatitis (Hepatotyphoid)
- Jaundice + hepatomegaly + elevated transaminases
- Must differentiate from viral hepatitis
- LFT: ALT/AST mildly elevated, bilirubin elevated
- Treated with standard antibiotics; avoid paracetamol excess
๐ท Typhoid Myocarditis
- Toxic myocarditis โ bradycardia, arrhythmias, ECG changes (ST/T wave changes)
- Can cause sudden death
- Dexamethasone may help; cardiology support
๐ท Typhoid Meningitis / Encephalopathy
- Rare but life-threatening
- Seizures, altered sensorium
- CSF: may show lymphocytic pleocytosis
- IV Ceftriaxone is preferred (good CNS penetration)
๐ท Typhoid Pneumonia (Pneumotyphoid)
- Dry cough, lobar or bronchopneumonia
- Often misdiagnosed as community-acquired pneumonia
๐ท Typhoidal Cholecystitis
- Acute cholecystitis during typhoid
- Salmonella colonizes gallbladder โ chronic carrier state
๐ท Typhoid Arthritis / Osteomyelitis
- Rare complication, especially in sickle cell patients
11. TREATMENT CHANGING PROTOCOLS โ DO's & DON'Ts
โ DO's
| Action | Rationale |
|---|---|
| Do send blood culture BEFORE starting antibiotics | Maximizes culture sensitivity |
| Do use azithromycin or ceftriaxone as first-line in India | Fluoroquinolone resistance is widespread |
| Do continue antibiotics for full course (7โ14 days) | Prevents relapse |
| Do monitor CBC, LFT, and clinical response every 3โ5 days | Detects complications early |
| Do switch to oral step-down after 5โ7 days IV if responding | Reduces hospital stay, cost |
| Do add dexamethasone in severe typhoid with CNS involvement/shock | Proven mortality reduction (Harrison's) |
| Do isolate patient and enforce strict hand hygiene | Prevent nosocomial spread |
| Do treat carriers (4-week ciprofloxacin) | Breaks transmission chain |
| Do rehydrate adequately | Maintains perfusion during toxemia |
| Do return to culture/sensitivity if no response in 72 hours | May indicate MDR/XDR strain |
โ DON'Ts
| Avoid | Reason |
|---|---|
| Don't use aspirin/NSAIDs for fever | Risk of GI hemorrhage + platelet dysfunction |
| Don't give high-dose paracetamol with hepatitis | Hepatotoxicity |
| Don't use antidiarrheal drugs (loperamide) | Prolongs carrier state; masks toxic megacolon |
| Don't stop antibiotics when fever settles | Relapse is common (5โ10%); complete full course |
| Don't use fluoroquinolones empirically in South Asia | Widespread nalidixic acid-resistant strains |
| Don't give purgatives or enemas | Risk of perforation |
| Don't do vigorous abdominal palpation | Can precipitate perforation |
| Don't give high-fiber/hard-to-digest food | Risk of perforation during ulcerative phase |
| Don't discharge patient without confirming clinical stability | Relapse and complications may occur |
| Don't use Widal test alone to diagnose in endemic areas | High false-positive rate; always correlate clinically |
12. DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS (DD)
Diagnosis Summary
- Definitive: Blood/bone marrow culture positive for S. Typhi
- Probable: Widal titer โฅ 1:160 (O or H) with clinical features + leukopenia + eosinopenia
- Rapid: Typhidot or Tubex positive
Differential Diagnosis
| Disease | Differentiating Features |
|---|---|
| Malaria | Paroxysmal chills + rigors; blood smear positive; thrombocytopenia prominent; Widal negative; responds to antimalarials |
| Dengue | Severe myalgia, retro-orbital pain, rash; NS1/IgM positive; severe thrombocytopenia + leukopenia + elevated hematocrit |
| Infective Endocarditis | Heart murmur, embolic phenomena, positive ECHO; blood culture shows Streptococcus/Staphylococcus |
| Viral Hepatitis | Jaundice prominent from start; very high ALT/AST; HAV/HBV serology positive |
| Tuberculosis | Prolonged fever > 4 weeks; night sweats, weight loss; AFB/CBNAAT positive; CXR abnormal |
| Brucellosis | Animal contact history; undulant fever; Rose Bengal test + |
| Leptospirosis | Weil's disease โ jaundice + AKI + conjunctival suffusion; exposure to contaminated water |
| Scrub Typhus | Eschar (pathognomonic); mite exposure; Weil-Felix positive; responds to doxycycline |
| Septicemia | Leukocytosis (not leukopenia); positive blood culture for other organisms |
| Lymphoma | Splenomegaly + constitutional symptoms but no acute toxic features; FNAC/biopsy diagnostic |
13. DRUG STUDY / COMBINATION
Antibiotic Mechanisms
| Drug | Class | Mechanism | Notes |
|---|---|---|---|
| Azithromycin | Macrolide | Binds 50S ribosome โ inhibits protein synthesis | Excellent intracellular penetration; concentrates in macrophages โ ideal for intracellular S. Typhi |
| Ceftriaxone | 3rd Gen Cephalosporin | Inhibits cell wall synthesis (PBP binding) | Parenteral; preferred in severe/hospitalized typhoid; excellent efficacy |
| Cefixime | 3rd Gen Cephalosporin (oral) | Same as ceftriaxone | Oral step-down option |
| Ciprofloxacin | Fluoroquinolone | Inhibits DNA gyrase (topoisomerase II) + topoisomerase IV | Now limited by resistance; only use if nalidixic acid-sensitive |
| Chloramphenicol | Amphenicol | Binds 50S ribosome | Historic gold standard; hepatotoxicity, aplastic anemia; now only for sensitive strains in low-resource settings |
| Ampicillin | Aminopenicillin | Beta-lactam (PBP binding) | Active only against sensitive strains; MDR strains resistant |
| Co-trimoxazole | Sulfonamide + Diaminopyrimidine | Inhibits folate synthesis (DHPS + DHFR) | MDR-resistant strains; used as adjunct |
| Meropenem | Carbapenem | Broad beta-lactam, PBP binding | Reserve for XDR typhoid |
| Dexamethasone | Corticosteroid | Reduces cytokine storm, endotoxin-mediated inflammation | ONLY in severe typhoid with altered consciousness/shock |
Drug Combinations (Special Scenarios)
| Situation | Combination |
|---|---|
| Severe hospitalized typhoid | Ceftriaxone IV ยฑ Azithromycin oral (sequential) |
| MDR typhoid | Ceftriaxone IV (10 days) |
| XDR typhoid | Azithromycin + Meropenem (severe) |
| Typhoid + hepatitis | Ceftriaxone (avoid hepatic metabolism burden); avoid chloramphenicol |
| Typhoid + CNS | Ceftriaxone IV (high CSF penetration) |
| Chronic carrier | Ciprofloxacin 750 mg BD ร 4 weeks OR + Cholecystectomy |
| Typhoid with toxemia/shock | Ceftriaxone + Dexamethasone IV |
โ ๏ธ Combination antibiotic therapy (e.g., two antibiotics simultaneously) is NOT standard for uncomplicated typhoid. Sequential step-down (IV โ oral) is preferred.
14. PATHYA (เคชเคฅเฅเคฏ) เคต APATHYA (เค เคชเคฅเฅเคฏ) โ Dietary & Lifestyle Guidelines
(Based on Ayurvedic principles + Modern clinical nutrition for typhoid)
โ PATHYA (Beneficial / What to Do)
Ahara (Diet)
| Food | Rationale |
|---|---|
| Rice gruel (Peya / Manda) | Light, easily digestible, soothing to GI tract |
| Thin khichdi (rice + moong dal) | Easily digestible protein + carbohydrate |
| Curd (fresh, not sour) | Probiotics; restores gut flora; easily assimilated |
| Buttermilk (Takra โ thin) | Digestive, cooling, Deepana (kindles digestive fire) |
| Coconut water | Electrolyte replenishment, cooling |
| Boiled/mashed vegetables (lauki, pumpkin, carrot) | Soft fiber, easily digested |
| Pomegranate juice | Digestive, styptic (useful in hemorrhagic tendency) |
| Banana (ripe) | Soft, easily digestible, potassium source |
| Moong dal soup | Laghu (light), Deepana, protein source |
| Sugarcane juice | Energy, cooling, diuretic |
| Boiled/ORS water | Essential hydration |
| Ginger tea (weak) | Deepana-Pachana; mild antiemetic |
Vihara (Lifestyle)
| Practice | Rationale |
|---|---|
| Complete bed rest | Prevents physical stress during bacteremia/ulceration phase |
| Good ventilation | Reduces fever discomfort |
| Personal hygiene | Hand washing, isolate utensils |
| Cool sponging | Manages hyperpyrexia |
| Mental calmness | Reduces Vata aggravation |
| Gradual mobilization in recovery | Avoid sudden exertion |
โ APATHYA (Harmful / What to Avoid)
Ahara (Diet)
| Food | Reason |
|---|---|
| Spicy, oily, fried food | Irritates intestinal ulcers; delays healing |
| Raw vegetables, salads | Hard to digest; can mechanically injure ulcerated bowel |
| Whole pulses (Rajma, Chana, Urad dal) | Guru (heavy), flatulence โ distension โ risk of perforation |
| Red meat / non-veg (hard) | Very heavy; increases ama (toxins); hard to digest |
| Milk in large quantity (acute phase) | Can be heavy; bloating; acceptable in small quantities during recovery |
| Cold drinks, ice cream | Worsen Vata; irritate inflamed gut |
| Alcohol | Hepatotoxic; immunosuppressive |
| High-fiber foods (whole grains, raw bran) | Risk of intestinal perforation in week 2โ3 |
| Street food / outside food | Source of reinfection |
| Fermented/sour foods (excess) | Aggravate Pitta; worsen intestinal inflammation |
Vihara (Lifestyle)
| Avoid | Reason |
|---|---|
| Strenuous exercise / lifting | Risk of splenic rupture + intestinal perforation |
| Vigorous abdominal massage | Can precipitate perforation |
| Suppression of natural urges | Vata aggravation; increased intraluminal pressure |
| Exposure to cold/rain | Depletes immunity; increases complications |
| Smoking | Immunosuppressive; delays mucosal healing |
| Self-medication / stopping antibiotics early | Leads to relapse and carrier state |
| Fasting | Weakens the already debilitated patient |
QUICK SUMMARY TABLE
| Domain | Key Point |
|---|---|
| Causative agent | Salmonella typhi |
| Route | Feco-oral |
| Pathogenesis hallmark | Intramacrophage survival via PhoP/PhoQ + T3SS |
| Classic presentation | Stepladder fever + relative bradycardia + rose spots + splenomegaly |
| Best diagnostic test | Blood culture (Week 1) / Bone marrow culture |
| CBC hallmark | Leukopenia + Eosinopenia |
| Recovery sign | Return of eosinophils |
| Drug of choice (India) | Azithromycin (oral) / Ceftriaxone (IV) |
| Avoid in treatment | NSAIDs, antidiarrheal agents, early antibiotic stoppage |
| Most feared complication | Intestinal perforation |
| Prognosis | Excellent with early, appropriate treatment |
| Pathya | Rice gruel, khichdi, coconut water, moong soup, rest |
| Apathya | Spicy/fried food, raw vegetables, whole pulses, strenuous activity |
Sources: Harrison's Principles of Internal Medicine, 21st Ed. (p. 4852); Bailey & Love's Short Practice of Surgery, 28th Ed. (p. 112); supplemented with WHO Typhoid Guidelines, IAP Guidelines, and standard clinical knowledge.
This is a shared conversation. Sign in to Orris to start your own chat.